Objective
To determine whether classes of diabetes medications are associated with cognitive health and dementia risk, above and beyond their glycemic control properties.
Research design and methods
Findings were pooled from 5 population-based cohorts: the Framingham Heart Study, the Rotterdam Study, the Atherosclerosis Risk in Communities (ARIC) Study, the Aging GeneEnvironment Susceptibility-Reykjavik Study (AGES) and the Sacramento Area Latino Study on Aging (SALSA). Differences between users and non-users of insulin, metformin and sulfonylurea were assessed in each cohort for cognitive and brain MRI measures using linear regression models, and cognitive decline and dementia/AD risk using mixed effect models and Cox regression analyses, respectively. Findings were then pooled using meta-analytic techniques, including 3,590 individuals with diabetes for the prospective analysis.
Results
After adjusting for potential confounders including indices of glycemic control, insulin use was associated with increased risk of new-onset dementia (pooled HR (95% CI) = 1.58

Additional Metadata
Persistent URL dx.doi.org/10.1002/uog.20201, hdl.handle.net/1765/115350
Journal Ultrasound in Obstetrics and Gynecology
Citation
Russo, F.M., Hooper, S., Tibboel, D, DeKoninck, P, Benachi, A, Treluyer, J.M., … Deprest, J. (2019). Antenatal therapy with sildenafil: don't throw the baby out with the bathwater. Ultrasound in Obstetrics and Gynecology, 53(2), 274–27+. doi:10.1002/uog.20201